Frankreich - Französisch - ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé)

arrow generiques - darunavir - comprimé - 400 mg - composition pour un comprimé > darunavir : 400 mg . sous forme de : darunavir propylène glycolate - antiviraux à usage systémique, inhibiteurs de protéase

Europäische Union - Französisch - EMA (European Medicines Agency)

viiv healthcare b.v. - cabotegavir sodium, cabotegravir - infections au vih - antiviraux à usage systémique - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna.

Europäische Union - Französisch - EMA (European Medicines Agency)

janssen-cilag international nv - rilpivirine - infections au vih - antiviraux à usage systémique - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.

Europäische Union - Französisch - EMA (European Medicines Agency)

viiv healthcare b.v. - cabotegravir - infections au vih - antiviraux à usage systémique - apretude is indicated in combination with safer sex practices for pre-exposure prophylaxis (prep) to reduce the risk of sexually acquired hiv-1 infection in high-risk adults and adolescents, weighing at least 35 kg (see sections 4. 2, 4. 4 et 5.

Israel - Englisch - Ministry of Health

j-c health care ltd - darunavir as ethanolate - film coated tablets - darunavir as ethanolate 400 mg - darunavir - darunavir - prezista , co-administered with 100 mg ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection for over 18 years of age.

Israel - Englisch - Ministry of Health

j-c health care ltd - darunavir as ethanolate - film coated tablets - darunavir as ethanolate 600 mg - darunavir - darunavir - prezista , co-administered with 100 mg ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv-1) infection for over 18 years of age.

Europäische Union - Englisch - EMA (European Medicines Agency)

janssen-cilag international n.v.    - rilpivirine hydrochloride - hiv infections - antivirals for systemic use - edurant, in combination with other antiretroviral medicinal products, is indicated for the treatment of human immunodeficiency virus type 1 (hiv‑1) infection in antiretroviral treatment‑naïve patients 12 years of age and older with a viral load ≤ 100,000 hiv‑1 rna copies/ml. as with other antiretroviral medicinal products, genotypic resistance testing should guide the use of edurant.,

Europäische Union - Englisch - EMA (European Medicines Agency)

gilead sciences international ltd  - emtricitabine, rilpivirine hydrochloride, tenofovir disoproxil fumarate - hiv infections - antivirals for systemic use - eviplera is indicated for the treatment of adults infected with human immunodeficiency virus type 1 (hiv-1) without known mutations associated with resistance to the non-nucleoside reverse transcriptase inhibitor (nnrti) class, tenofovir or emtricitabine, and with a viral load ≤ 100,000 hiv-1 rna copies/ml. as with other antiretroviral medicinal products, genotypic resistance testing and/or historical resistance data should guide the use of eviplera.

Europäische Union - Englisch - EMA (European Medicines Agency)

gilead sciences ireland uc - emtricitabine, rilpivirine hydrochloride, tenofovir alafenamide - hiv infections - antivirals for systemic use - treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (hiv 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (nnrti) class, tenofovir or emtricitabine and with a viral load ≤ 100,000 hiv 1 rna copies/ml.,

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

american health packaging - sirolimus (unii: w36zg6ft64) (sirolimus - unii:w36zg6ft64) - sirolimus 0.5 mg - sirolimus tablets are indicated for the prophylaxis of organ rejection in patients aged 13 years or older receiving renal transplants. in patients at low- to moderate-immunologic risk, it is recommended that sirolimus tablets be used initially in a regimen with cyclosporine and corticosteroids; cyclosporine should be withdrawn 2 to 4 months after transplantation [see dosage and administration ( 2.2)]. in patients at high-immunologic risk (defined as black recipients and/or repeat renal transplant recipients who lost a previous allograft for immunologic reason and/or patients with high panel-reactive antibodies [pra; peak pra level > 80%]), it is recommended that sirolimus tablets be used in combination with cyclosporine and corticosteroids for the first year following transplantation [see dosage and administration ( 2.3), clinical studies ( 14.3)]. cyclosporine withdrawal has not been studied in patients with banff grade 3 acute rejection or vascular rejection prior to cyclosporine withdrawal, those who are